Germany's Pioneering DIGA Act Spurs Digital Health Innovation, With Limits While the RCTs required to meet DiGA’s standards are not as onerous as traditional pharmaceutical pivotal trials, they are still time-consuming, and the statue allows manufacturers to get an extendable one-year listing based on preliminary evidence, which enables them to generate revenue while they complete the more rigorous studies required for a permanent listing (see Figure 1 below). Germany’s high-profile DiGA legislation has successfully encouraged digital therapeutics innovation, according to two new studies, although critics say it still leaves room for improvement. The US company Enovis, which embraces digital therapeutics as a promising business, and its German start-up partner Orthopy Health GmbH are testing the DiGA waters in what Enovis considers to be an important ex-US market opportunity: https://bit.ly/4eWlwj6 #digitaltherapeutics #digitalhealth #medtechinnovation #digitalhealthinnovation #Germany #medtech
Market Pathways’ Post
More Relevant Posts
-
International Business Development, In & Out Licensing MENA/EU, Alliances & partnering. Certified NXU MBA holder, Certified project management professional PMP®
Let’s connect and create impactful solutions for a healthier future! EVA pharma RauCon Business Development See you in Dublin! 🌟 . . . . . . #EuroPLX #PharmaIndustry #BusinessDevelopment #Partnerships #Collaboration #Innovation #Healthcare #Biotech #Pharmaceuticals #LifeSciences #DrugDevelopment #HealthcareInnovation #ClinicalResearch #PharmaBusiness #HealthTech #GlobalHealth #MedicalResearch #PharmaPartnerships #BusinessGrowth #IndustryLeaders #HealthSolution
We are thrilled to announce that EVA Pharma's business development team will be participating in EuroPLX, Dublin on the 3rd and 4th of June 2024. Our team is eager to explore new business collaborations and forge strong partnerships with pharmaceutical industry leaders. Together, we can empower the fight for health and well-being & ensure healthcare access to all people globally! See you in Dublin! RauCon Business Development #EuroPLX #EVAPharma
-
-
Radio Romania from Romania also reported on the launch of the Public Pharma for Europe coalition. The publication highlighted that the group emphasizes the argument that the current profit-driven pharmaceutical model is characterised by several dysfunctions that significantly hinder the global realisation of the right to health. These dysfunctions result in a lack of innovation, the private appropriation of public resources, shortages of essential health technologies, exorbitant medication prices, evidence-biased clinical trials, and distortions in drug prescriptions. They also deepen tensions and inequities between the Global North and the Global South. 🔗Check out the news (in Romanian): https://lnkd.in/etn9nD63 #PPfE #PublicPharma #publicpharmaeurope
-
-
Africa’s Healthcare Uprising: Medicine Manufacturers Kickstart a Revolution to Redefine the Continent’s Future AMMTEC 2024 unites Africa’s pharmaceutical industry to spark a healthcare transformation 2 December 2024 – The close of the first African Medicines Manufacturing Trade Exhibition and Conference (AMMTEC) ushers in a new era of energy and commitment, shaking up the status quo in the manufacturing of medicines for the continent’s health systems.... lire la suite https://lnkd.in/e43RPHj9 #AMMTEC #Event #Conference #TradeExhibition #pharmaceuticalindustry #Logistafrica
-
-
Chief Commercial Officer | Chief Medical Officer | Board | Surgeon | Mentor | Digital Health
Tomorrow I'll be speaking at the Digital Health Nexus conference on the 'Intersection between the Healthcare Provider & Pharmaceutical Industry In Digital Health Innovation'. I'll be discussing the potential for partnerships between NHS providers, digital innovators, and the pharmaceutical sector, while addressing common challenges and offering advice for achieving effective collaboration. Looking forward to connecting with attendees and feel free to share your thoughts on the topic! Nexus Conference ABHI Open Medical #digitalhealth #healthtech #healthcareinnovation #pharma #digitaltransformation #nhs
-
-
🌟CALLING ALL PHARMACEUTICAL PROFESSIONALS! Join us at the WOCIP Cluster Meetings, where collaboration sparks innovation! See the exciting topics covered in all four targeted business meetings below! Stay tuned as we unveil the unique topics for each day! Join forces with peers in your role across the industry to tackle barriers to health equity together! 🌎 REGISTER BY APRIL 12th AND GET 50% OFF. Use the link and code in the comments. #WOCIP #HealthEquity #PharmaIndustry
-
-
👏 What a great visual summary of Mobilise-D 's conference! 👀 You can download it from their website: https://lnkd.in/eNQ9-chk 👉 Mobility – how well we walk – is an important marker of health; a slow walking speed is associated with a greater risk of disease, cognitive decline, risk of falls and even earlier death.The project is analysing gait based on digital technologies, including sensors worn on the body. #DigitalHealth #MobilityResearch #HealthResearch #IHITransformingHealth
👀🌟 Check out the awesome visual summary of our Mobilise-D Conference 2024 in Edinburgh! You can download the visual minutes from our Press and Promotion page here: https://lnkd.in/d_ZfhBBE #MobiliseD #DigitalHealth #ConferenceHighlights Innovative Health Initiative (IHI) EFPIA - European Federation of Pharmaceutical Industries and Associations
-
-
Spotlight on Pharma Innovators at Mobile in Clinical Trials 2024 -- As we gear up for this year's conference, we want to highlight the 15 confirmed pharmaceutical companies that are set to take the stage. These companies are not just participants; they are leaders in transforming clinical trials through mobile health technology, making research more efficient and patient-centric. Stay tuned for updates and learn more: https://lnkd.in/ggv8w76s #MobileClin2024 #MobileInClinicalTrials #PharmaInnovation #ClinicalResearch #HealthcareTechnology #PharmaLeaders #DigitalHealth #MobileHealth
-
-
Real world outcomes measurement is no longer a nice to have for life science industry. Post launch evidence generation requirements by HTA bodies makes it necessity to have established partnerships in place to collect real time outcomes together with healthcare providers. Join us to discuss the topic in our webinar!
Join our webinar on May 30th to discover how Value-Based Healthcare (VBHC) is reshaping the pharmaceutical industry. Learn from experts Vesa Komssi, Nordic Healthcare Group's Executive Vice President, and Mark Tolboom, partner at Vintura, about enhancing patient access to innovative therapies and successful VBHC initiatives. Explore the power of partnership in driving innovation and improving treatment outcomes. Register now for insights into building a patient-centric healthcare system: https://lnkd.in/diC_Z6RU #EUHTA #VBHC #ValueBasedHealthcare #PatientOutcomes #HealthcareTransformation
-
-
A real transformation in drug prices in US (#IRA) making healthcare more accessible, affordable and available. We are entering a new era of regulated drug pricing similar to EU and Asian countries. Pharma Cos must adapt their strategies to the new negotiating landscape. 💡 Dive into our study, which showcases the pivotal IRA provisions and the implications for pharmaceutical companies and patients: ➡ https://lnkd.in/d2wbv3bn #RolandBerger ✍ Filip Conic Matthias Bünte Atsushi Kiyoizumi Thilo Kaltenbach Michael Baur Prof. Dr. Torsten Henzelmann Julien Gautier Anne Moore, PhD Hans Nyctelius Koen Besteman Kai Balder Stephan Fath Marco Bühren Yoshihiro Suwa Aditya Agarwal Lennart Boesch Omer Saka Sara Barada Salil Churi
-
In supporting the submission process for one of six therapies that received a positive NICE recommendation as part of phase 1 of the proportionate approach to technology appraisals (PATT), we at Stratenym immediately became aware of the challenges involved in this fast-paced process. Nevertheless, the end result of phase 1 of the PATT is evident - faster access to much-needed therapies. With phase 2 of the PATT now underway, NICE will be directing attention to four work strands, including enacting the pathways approach, which aims to use a central economic model to demonstrate cost-effectiveness for all therapies within a common disease area. The Association of the British Pharmaceutical Industry (ABPI) has voiced potential concerns with this approach but notes that continuous review of key milestones is important. With this in mind, we eagerly await the anticipated Q2 report from NICE on learnings from two pilot appraisals (ID6186 and ID6234) using the pathways approach, while keeping in mind the overarching goal - to decrease the time needed to accurately appraise novel therapies and enable faster access for patients. #NICE #Proportionateapproach #HTA #Marketaccess
-
